Meeting
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
Authors
Carolyn Moloney
Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
Carolyn Moloney , Tarik Demir , Liam IL Young Chung , Youjin Oh , Young Kwang Chae
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8645)
DOI
10.1200/JCO.2024.42.16_suppl.8645
Abstract #
8645
Poster Bd #
509
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Quality Care Symposium
A data driven approach to immunotherapy toxicity management.
First Author: Sadiqa Mahmood
First Author: Jeddeo Paul
Poster
2020 Gastrointestinal Cancers Symposium
Predictors of immunotherapy (IO) response in hepatocellular carcinoma (HCC).
First Author: Samantha Ann Armstrong
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna